| Literature DB >> 25302705 |
Yan Huang1, Sheng-Feng Lu2, Chen-Jun Hu3, Shu-Ping Fu4, Wei-Xing Shen5, Wan-Xin Liu6, Qian Li7, Ning Wang8, Su-Yun He9, Fan-Rong Liang10, Bing-Mei Zhu11.
Abstract
This study investigated genome-wide gene expressions and the cardioprotective effects of electro-acupuncture pretreatment at the PC6 Neiguan acupoint on myocardial ischemia reperfusion (I/R) injury. Male SD rats were randomly divided into four groups: sham operation (SO), I/R, electro-acupuncture at the PC6 Neiguan acupoint pretreatment (EA) and electro-acupuncture at non-acupoint pretreatment (NA). Compared with the I/R group, the survival rate of the EA group was significantly increased, the arrhythmia score, infarction area, serum concentrations of CK, LDH and CK-Mb and plasma level of cTnT were significantly decreased. RNA-seq results showed that 725 genes were up-regulated and 861 genes were down-regulated under I/R conditions compared to the SO group; both EA and NA reversed some of these gene expression levels (592 in EA and 238 in NA group). KEGG pathway analysis indicated that these genes were involved in multiple pathways, including ECM, MAPK signaling, apoptosis, cytokine and leukocyte pathways. In addition, some pathways were uniquely regulated by EA, but not NA pretreatment, such as oxidative stress, cardiac muscle contraction, gap junction, vascular smooth muscle contraction, hypertrophic, NOD-like receptor, and P53 and B-cell receptor pathways. This study was first to reveal the gene expression signatures of acute myocardial I/R injury and electro-acupuncture pretreatment in rats.Entities:
Mesh:
Year: 2014 PMID: 25302705 PMCID: PMC6271995 DOI: 10.3390/molecules191016158
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Anti-arrhythmic effect of EA. (A) Kaplan-Meier survival plots in 4 groups: SO (n = 15), I/R (n = 15), EA (n = 15), and NA (n = 15); (B) Representative ECG records measured from SO, I/R, EA, and NA rats. MI, myocardial ischemia; SR, sinus rhythm; VPC, ventricular premature contraction; VT, ventricular tachycardia; VF, ventricular fibrillation; (C) Quantitative analysis for arrhythmia scores. * p < 0.05, compared with SO group, #, p < 0.05, in comparison with I/R group (n = 15 for each group).
Figure 2Pretreatment with EA reduced infarct size and myocardial enzymes. (A) Representative TTC staining of the hearts harvested from SO, I/R, EA, and NA groups; (B) Infarct size percentage measured by Image J. * p < 0.05, compared with SO group, # p < 0.05, in comparison with I/R group. n = 5 in SO, n = 4 in I/R, n = 5 in EA, n = 5 in NA; (C–F) Effect of EA pretreatment on myocardial enzyme levels, including LDH, CK, CK-Mb, and cTnT released into serum and plasma after myocardial ischemia reperfusion in rats. * p < 0.05, compared with SO group, # p < 0.05, in comparison with I/R group. U/L, Units/Litre. n = 15 in SO, n = 6 in I/R, n = 11 in EA, n = 8 in NA.
DEGs across four groups.
| DEGs | I/R:SO | EA:I/R | NA:I/R |
|---|---|---|---|
| Up regulated | 725 | 385 | 364 |
| Down regulated | 861 | 649 | 355 |
| Total | 1586 | 1034 | 719 |
Figure 3Venn diagrams and clustering analysis of RNA-seq results. (A–D) Venn diagrams were drawn based on our RNA-seq data sets. Red circles indicate the numbers of genes up- or down-regulated in I/R group (vs. SO group); green circles in (A,C) represent the numbers of down- or up-regulated genes in the EA group (vs. I/R group). Blue circles in (B,D) represent the numbers of down- or up-regulated genes in the NA group (vs. I/R group). The heatmaps were created with up-regulated (E) and down‑regulated (F) DEGs in myocardial I/R injury. Expression levels of up-regulated and down-regulated genes are represented in red or green colors, respectively. Two dendrograms of hierarchical clustering of 8 samples using the 725 up-regulated genes in I/R group (G) and the 861 down-regulated genes in the I/R group (H).
The top 30 differentially expressed genes with a log2 (FC) > |±1|.
| A: The Top 30 Up-Regulated Genes in I/R | ||||
|---|---|---|---|---|
| Gene Name | Description | I/R | EA | NA |
| Hspa1b | heat shock 70 kD protein 1B | 3.58 | −1.12 | 0.97 |
| Mir3074 | microRNA 3074 | 3.1 | −3.13 | 0.6 |
| Kbtbd5 | kelch repeat and BTB (POZ) domain containing 5 | 3.04 | −2.87 | −0.39 |
| Fam46b | family with sequence similarity 46, member B | 2.7 | −1.44 | −1.15 |
| Hist1h1d | histone cluster 1, H1d | 2.7 | - | −1.85 |
| Tnfrsf12a | tumor necrosis factor receptor superfamily, member 12A | 2.67 | −2.39 | −0.43 |
| Fos | FBJ osteosarcoma oncogene | 2.57 | −1.18 | −1.15 |
| Atf3 | activating transcription factor 3 | 2.5 | −1.31 | −0.72 |
| Has1 | hyaluronan synthase 1 | 2.47 | −1.83 | −0.31 |
| Camp | cathelicidin antimicrobial peptide | 2.46 | −0.06 | 1.3 |
| Mir3556b | microRNA 3556b | 2.37 | - | - |
| Vdac3 | voltage-dependent anion channel 3 | 2.28 | 0.3 | −0.14 |
| Trh | thyrotropin releasing hormone | 2.24 | −2.14 | −2.75 |
| Hmox1 | hemeoxygenase (decycling) 1 | 2.23 | −0.78 | 0.7 |
| Cyr61 | cysteine-rich, angiogenic inducer, 61 | 2.22 | −0.98 | −0.09 |
| Pgf | placental growth factor | 2.21 | −1.81 | 0.32 |
| Slc7a5 | solute carrier family 7, member 5 | 2.21 | −1.33 | −0.08 |
| Klk12 | kallikrein related-peptidase 12 | 2.09 | −1.5 | −1.81 |
| Sphk1 | sphingosine kinase 1 | 2.09 | −1.74 | −0.72 |
| Cblc | Cbl proto-oncogene C, E3 ubiquitin protein ligase | 2.03 | −1.84 | −2.24 |
| Nr4a1 | nuclear receptor subfamily 4, group A, member 1 | 2 | −0.72 | −2.35 |
| Numbl | numb homolog (Drosophila)-like | 2 | −1.58 | −1.14 |
| Mt1a | metallothionein 1A | 1.97 | −1.77 | −0.44 |
| Flnc | filamin C, gamma | 1.95 | −1.69 | 0.14 |
| Lcn2 | lipocalin 2 | 1.95 | −0.84 | −3.48 |
| Gal | Galanin | 1.94 | −1.32 | −1.67 |
| Alox15 | arachidonate 15-lipoxygenase | 1.94 | −1.74 | −0.66 |
| Akr1b8 | aldo-keto reductase family 1, member B8 | 1.94 | −1.19 | −0.41 |
| Mt2A | metallothionein 2A | 1.9 | −0.8 | 0.62 |
| Cnot3 | CCR4-NOT transcription complex, subunit 3 | 1.89 | −1.47 | −1.13 |
| LOC367975 | unknown | −5.86 | 2.19 | 2.72 |
| Mir145 | microRNA 145 | −5.32 | - | - |
| Klre1 | killer cell lectin-like receptor family E member 1 | −4.58 | 4.27 | 4.8 |
| Ky | kyphoscoliosis peptidase | −3.62 | 0.78 | 0.42 |
| Clecsf6 | C-type lectin domain family 4, member A | −3.45 | 2.68 | 1.56 |
| RGD1306750 | unknown | −3.21 | 2.09 | 1.78 |
| Cybb | cytochrome b-245, beta polypeptide | −2.83 | 2.38 | 2.45 |
| Ptplad2 | protein tyrosine phosphatase-like A domain containing 2 | −2.78 | 1.91 | 0.86 |
| Cyp2e1 | cytochrome P450, family 2, subfamily E, polypeptide 1 | −2.74 | 2.82 | −0.38 |
| Sh2d1a | SH2 domain containing 1A | −2.71 | 2.4 | 2.73 |
| Tas2r120 | taste receptor, type 2, member 120 | −2.6 | 1.95 | 0.92 |
| Epsti1 | epithelial stromal interaction 1 | −2.57 | 1.84 | 1.74 |
| C6 | complement component 6 | −2.56 | 1.35 | 1.54 |
| F13a1 | coagulation factor XIII, A1 polypeptide | −2.54 | 1.9 | 1.17 |
| Bex4 | brain expressed, X-linked 4 | −2.5 | 1.31 | 1.05 |
| Tfec | transcription factor EC | −2.5 | 2.58 | 2.16 |
| Msr1 | macrophage scavenger receptor 1 | −2.48 | 2.15 | 3.17 |
| Ptprc | protein tyrosine phosphatase, receptor type, C | −2.47 | 0.3 | 1.93 |
| Clec4a2 | C-type lectin domain family 4, member A2 | −2.45 | 2.31 | 1.75 |
| Cd69 | CD69molecule | −2.42 | 1.89 | 1.04 |
| Agr2 | anterior gradient 2 | −2.41 | 0.25 | 1.26 |
| Igsf6 | immunoglobulin superfamily, member 6 | −2.41 | 1.73 | 2.51 |
| Lilra5 | leukocyte immunoglobulin-like receptor, subfamily A, member 5 | −2.38 | 2.06 | −0.23 |
| Klri1 | killer cell lectin-like receptor family I member 1 | −2.34 | 2.18 | 1.73 |
| Ubd | ubiquitin D | −2.32 | 0.46 | 0.98 |
| Ahr | aryl hydrocarbon receptor | −2.32 | 1.78 | 1.33 |
| Ccr2 | chemokine (C-C motif) receptor 2 | −2.31 | 2.52 | 2.7 |
| Pkhd1l1 | polycystic kidney and hepatic disease 1-like 1 | −2.31 | 2.03 | 1.45 |
| Mpeg1 | macrophage expressed 1 | −2.29 | 2.07 | 2.25 |
| Dock11 | dedicator of cytokinesis 11 | −2.28 | 1.62 | 1.19 |
Specified values of log2 (log2 FC|±1) refer to SO in I/R, and to I/R in EA and NA. Minus refers to down-regulation; “-” represents data not available.
Figure 4Pathways analysis. (A–D) Pathways of these overlap genes were analyzed using KEGG pathway program, based on individual over lapped gene numbers shown in Figure 3. (A) was drawn from the 317 genes shown in Figure 3A; (B) from the 275 genes in Figure 3C; (C) from the 111 genes in Figure 3B; (D) from the 127 genes in Figure 3D.
Figure 5qRT-PCR validation of RNA-seq results. Comparison of fold change (log2) in differential expression values determined by RNA-seq (black) and qRT-PCR (spodoptera) for DEGs.
Figure 6Experimental protocol. See Experimental Section 3.4 for grouping and treatments. EA group (n = 15); NA group (n = 15); I/R group (n = 15); SO group (n = 15). EA, electro-acupuncture at PC6 Neiguan acupoint. NA, electro-acupuncture at the base point of the tail. I, ischemia. R, reperfusion.